Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : C-Cube -- Ignore unavailable to you. Want to Upgrade?

To: Stoctrash who wrote (35030)	8/7/1998 9:48:00 AM
From: Jan Crawley	Read Replies (1) \| Respond to of 50808

Its up to 18 3/4. I bought Cube at $15 3/4!!! :))

To: Stoctrash who wrote (35030)	8/7/1998 12:12:00 PM
From: Biotech Jim	Respond to of 50808

OT: I have no idea why the rise in AMGN, but I do feel that their product pipeline is considered by many to be weak and that the slowing growth of their 2 established products is evident. Nonetheless they are a cash cow currently. I would look at NPSP as a possible buy since AMGN is supporting some of their clinical trials and they are near a yearly low. There are other smallcap biotechs that are on the radar screen, as was CUBE when it dropped to the mid teens. In a couple of years there should be some home runs for some of those above as well as others that I can mention in a private reply. Don't want to clog up this thread. BJ